LXRX: Held by 4 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Home›Companies›LEXICON PHARMACEUTICALS, INC. (LXRX)

LEXICON PHARMACEUTICALS, INC.

LXRX

Held by 4 specialist biotech funds

High Convergence

4 funds opened new positions.

Score Holdings Short Interest Catalysts Insiders Research

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback

Signal Score

5.0/10

4 funds opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 4 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

4 fund convergence

Tang Capital Management

BVF Partners

Deerfield Management

OrbiMed Advisors

Position history (shares)

Tang Capital Management

OrbiMed Advisors

4 quarters

Position Trend

May 15, 2025

$530K

1 fund

Aug 14, 2025

0 funds

Nov 14, 2025

0 funds

Feb 17, 2026

0 funds

-100% total institutional value over 12 quarters

Catalysts

No catalysts tracked.

Position Details

Tang Capital ManagementEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

34 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

AAVXF1 fund ADCT1 fund ACET1 fund ALNY1 fund ANRO1 fund ALMS1 fund FOLD1 fund APLS1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer